SZSE:301201 (China)
Â
Class A
Â¥
37.94
+0.84 (+2.26%)
Jul 15
Business Description
Chengda Pharmaceuticals Co Ltd
ISIN : CNE100005766
Share Class Description:
SZSE:301201: Class ATotal Employee Number:
659Compare
Compare
Traded in other countries / regions
301201.China IPO Date
2022-01-20Description
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.31 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -202.45 | |||||
Interest Coverage | 13.79 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 15.95 | |||||
Beneish M-Score | -2.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.4 | |||||
3-Year EBITDA Growth Rate | -26.4 | |||||
3-Year FCF Growth Rate | 39.5 | |||||
3-Year Book Growth Rate | -1.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.49 | |||||
9-Day RSI | 50.73 | |||||
14-Day RSI | 51.09 | |||||
3-1 Month Momentum % | -25.77 | |||||
6-1 Month Momentum % | -25.35 | |||||
12-1 Month Momentum % | 38.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.57 | |||||
Quick Ratio | 6.72 | |||||
Cash Ratio | 5.61 | |||||
Days Inventory | 195.05 | |||||
Days Sales Outstanding | 94.1 | |||||
Days Payable | 199.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.54 | |||||
Dividend Payout Ratio | 1.45 | |||||
3-Year Dividend Growth Rate | -10.7 | |||||
Forward Dividend Yield % | 0.54 | |||||
5-Year Yield-on-Cost % | 0.53 | |||||
Shareholder Yield % | 0.37 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.43 | |||||
Operating Margin % | 5.29 | |||||
Net Margin % | -0.77 | |||||
EBITDA Margin % | -0.06 | |||||
FCF Margin % | -2.75 | |||||
OCF Margin % | 9.94 | |||||
ROE % | -0.17 | |||||
ROA % | -0.15 | |||||
ROIC % | 2.05 | |||||
3-Year ROIIC % | -21.02 | |||||
ROC (Joel Greenblatt) % | -0.03 | |||||
ROCE % | -0.01 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 274.93 | |||||
Shiller PE Ratio | 90.33 | |||||
PS Ratio | 12.52 | |||||
PB Ratio | 2.79 | |||||
Price-to-Tangible-Book | 2.84 | |||||
Price-to-Operating-Cash-Flow | 125.23 | |||||
EV-to-EBIT | -17356.2 | |||||
EV-to-EBITDA | -17356.2 | |||||
EV-to-Revenue | 11.06 | |||||
EV-to-FCF | -401.39 | |||||
Price-to-GF-Value | 1.25 | |||||
Price-to-Projected-FCF | 5.73 | |||||
Price-to-Graham-Number | 5.89 | |||||
| Price-to-Net-Current-Asset-Value | 5.48 | |||||
| Price-to-Net-Cash | 8 | |||||
Earnings Yield (Greenblatt) % | -0.01 | |||||
FCF Yield % | -0.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chengda Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 458.304 | ||
| EPS (TTM) (Â¥) | -0.023 | ||
| Beta | 0.6308 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 66.63 | ||
| 14-Day RSI | 51.09 | ||
| 14-Day ATR (Â¥) | 3.050022 | ||
| 20-Day SMA (Â¥) | 37.7455 | ||
| 12-1 Month Momentum % | 38.88 | ||
| 52-Week Range (Â¥) | 23.81 - 65.03 | ||
| Shares Outstanding (Mil) | 154.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chengda Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chengda Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.200000 Cash Dividend | 2026-07-15 | 37.30 (-1.43%) | ||
| CNY 0.200000 Cash Dividend | 2025-07-10 | 23.05 (-0.86%) | ||
| 1.6:1 Stock Split | 2023-07-07 | 26.09 (+0.19%) |
Show
Entries
Chengda Pharmaceuticals Co Ltd Frequently Asked Questions
What is Chengda Pharmaceuticals Co Ltd(SZSE:301201)'s stock price today?
The current price of SZSE:301201 is ¥37.94. The 52 week high of SZSE:301201 is ¥65.03 and 52 week low is ¥23.81.
When is next earnings date of Chengda Pharmaceuticals Co Ltd(SZSE:301201)?
The next earnings date of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is .
Does Chengda Pharmaceuticals Co Ltd(SZSE:301201) pay dividends? If so, how much?
The Dividend Yield %  of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is 0.54% (As of Today), Highest Dividend Payout Ratio of Chengda Pharmaceuticals Co Ltd(SZSE:301201) was 1.45. The lowest was 0.62. And the median was 0.74. The  Forward Dividend Yield % of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is 0.54%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Chengda Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers